[The prognostic value of a modified WPSS based on routine laboratory parameters in patients with myelodysplastic syndromes: a preliminary result].
OBJECTIVE
To investigate the prognostic value of a modified WPSS based on routine laboratory parameters in Chinese patients with myelodysplastic syndromes (MDS).


METHODS
One hundred and sixty four adult MDS patients were retrospectively analyzed.


RESULTS
The median follow-up time was 19 (1-138) months and the median survival (MS) was 36 months. 2-year prospective survival (PS) was 60% and 5-year PS was 42%. In patients with very low-risk, low-risk, intermediate-risk, high-risk and very high-risk stratified by WPSS, 2-year PS was 100%, 96%, 81%, 38% and 14%, and 5-year PS was 100%, 83%, 54%, 20% and 0, respectively (P<0.01). Among parameters of laboratory routine examination, elevated mean cell volume (MCV), mean cell hemoglobin (MCH), neutrophil alkaline phosphatase (N-ALP) index and nucleated RBC PAS negative were good prognostic factors, while reduced Hb, BPC and bone marrow elevated blasts, dysplasia more than 1 lineage, and lymphocyte-like micromegakaryocyte (MEGly) as well as elevated serum LDH were poor prognostic factors in uni-variable analysis. Among them, MCV, MEGly and blast had independent prognostic significance in multi-variable analysis (P = 0.011, 0.013 and 0.016, respectively). WPSS was modified by omitting chromosomal karyotype and transfusion dependence and adding MCV and MEGly. In patients with low-risk, intermediate-risk and high-risk stratified by modified WPSS, 2-year PS was 94%, 68% and 49%, respectively; and 5-year PS was 86%, 53% and 14%, respectively (P<0.01).


CONCLUSIONS
The modified WPSS worked well for prognostic prediction in Chinese patients with MDS.
Li
Lin
L
Institute of Hematology and Blood Diseases Hospital, CAMS, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.
Nie
Ling
L
Yu
Ming-hua
MH
Yu
Yang
Y
Liu
Liang
L
Qin
Tie-jun
TJ
Xu
Ze-feng
ZF
Zhang
Yue
Y
Xiao
Zhi-jian
ZJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis*; D011379:Prognosis; D012189:Retrospective Studies; D055815:Young Adult